Bibliometric analysis of monoclonal antibodies for atherosclerosis

Endovascular revascularization strategies for aortoiliac and femoropopliteal artery disease: a meta-analysis

(2023) David Koeckerling et al.   EUROPEAN HEART JOURNAL

Endogenous IL-1 receptor antagonist restricts healthy and malignant myeloproliferation

(2023) Alicia Villatoro et al.   Nature Communications

Global research trends on immunotherapy in cancer: A bibliometric analysis

(2023) Zhichao Yao et al.   Human Vaccines & Immunotherapeutics

A Bibliometric Analysis of Familial Hypercholesterolemia From 2011 to 2021

(2022) Namin Wei et al.   CURRENT PROBLEMS IN CARDIOLOGY

Effect of Alirocumab Added to High-Intensity Statin Therapy on Coronary Atherosclerosis in Patients With Acute Myocardial Infarction

(2022) Lorenz Räber et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

TET2-Driven Clonal Hematopoiesis and Response to Canakinumab

(2022) Eric C. Svensson et al.   JAMA Cardiology

Interventional hepatic ApoC-III knockdown improves atherosclerotic plaque stability and remodeling upon triglyceride lowering

(2022) Bastian Ramms et al.   JCI Insight

Targeting of Scavenger Receptors Stabilin-1 and Stabilin-2 Ameliorates Atherosclerosis by a Plasma Proteome Switch Mediating Monocyte/Macrophage Suppression

(2022) Calin-Petru Manta et al.   CIRCULATION

Long-Term Evolocumab in Patients With Established Atherosclerotic Cardiovascular Disease

(2022) Michelle L. O’Donoghue et al.   CIRCULATION

Combination of ezetimibe and moderate-intensity statin for patients with atherosclerotic cardiovascular disease: a paradigm shift in lipid management landscape

(2022) Daniela Pedicino et al.   EUROPEAN HEART JOURNAL

Matrix metaloproteinases in vascular pathology

(2022) Gonçalo Simões et al.   MICROVASCULAR RESEARCH

Paediatric patients with heterozygous familial hypercholesterolaemia treated with evolocumab for 80 weeks (HAUSER-OLE): a single-arm, multicentre, open-label extension of HAUSER-RCT

(2022) Raul D Santos et al.   Lancet Diabetes & Endocrinology

Moderate-intensity statin with ezetimibe vs. high-intensity statin in patients with diabetes and atherosclerotic cardiovascular disease in the RACING trial

(2022) Yong-Joon Lee et al.   EUROPEAN HEART JOURNAL

Passive Prophylactic Administration with a Single Dose of Anti-Fel d 1 Monoclonal Antibodies REGN1908-1909 in Cat Allergen-Induced Allergic Rhinitis: A Randomized, Double-blind, Placebo Controlled Trial

(2021) Mohamed H Shamji et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

Evinacumab: First Approval

(2021) Anthony Markham   DRUGS

IL-6 inhibition with ziltivekimab in patients at high atherosclerotic risk (RESCUE): a double-blind, randomised, placebo-controlled, phase 2 trial

(2021) Paul M Ridker et al.   LANCET

Cholesterol metabolism: a new molecular switch to control inflammation

(2021) Diana Cardoso et al.   CLINICAL SCIENCE

Cholesterol efflux pathways, inflammation, and atherosclerosis

(2021) Anouk G. Groenen et al.   CRITICAL REVIEWS IN BIOCHEMISTRY AND MOLECULAR BIOLOGY

Extracellular matrix: paving the way to the newest trends in atherosclerosis

(2021) Chrysostomi Gialeli et al.   CURRENT OPINION IN LIPIDOLOGY

Global and regional prevalence, burden, and risk factors for carotid atherosclerosis: a systematic review, meta-analysis, and modelling study

(2020) Peige Song et al.   Lancet Global Health

Evinacumab in Patients with Refractory Hypercholesterolemia

(2020) Robert S. Rosenson et al.   NEW ENGLAND JOURNAL OF MEDICINE

Atheroprotective roles of smooth muscle cell phenotypic modulation and the TCF21 disease gene as revealed by single-cell analysis

(2019) Robert C. Wirka et al.   NATURE MEDICINE

Atherosclerosis

(2019) Peter Libby et al.   Nature Reviews Disease Primers

The pharmacodynamic and clinical trial evidence for statin dose

(2018) Simon B. Dimmitt et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

NLRP3 Inflammasome and the IL-1 Pathway in Atherosclerosis

(2018) Alena Grebe et al.   CIRCULATION RESEARCH

Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial

(2018) Paul M Ridker et al.   LANCET

Effect of Evolocumab on Coronary Plaque Composition

(2018) Stephen J. Nicholls et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome

(2018) Gregory G. Schwartz et al.   NEW ENGLAND JOURNAL OF MEDICINE

PCSK9 monoclonal antibodies reverse the pro-inflammatory profile of monocytes in familial hypercholesterolaemia

(2017) Sophie J. Bernelot Moens et al.   EUROPEAN HEART JOURNAL

Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease

(2017) Marc S. Sabatine et al.   NEW ENGLAND JOURNAL OF MEDICINE

Genetic and Pharmacologic Inactivation of ANGPTL3 and Cardiovascular Disease

(2017) Frederick E. Dewey et al.   NEW ENGLAND JOURNAL OF MEDICINE

Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease

(2017) Paul M Ridker et al.   NEW ENGLAND JOURNAL OF MEDICINE

Hyperlipidemia-induced cholesterol crystal production by endothelial cells promotes atherogenesis

(2017) Yvonne Baumer et al.   Nature Communications

From C-Reactive Protein to Interleukin-6 to Interleukin-1

(2016) Paul M Ridker   CIRCULATION RESEARCH

Effect of Evolocumab on Progression of Coronary Disease in Statin-Treated Patients

(2016) Stephen J. Nicholls et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: Rationale and design of the ODYSSEY Outcomes trial

(2014) Gregory G. Schwartz et al.   AMERICAN HEART JOURNAL

Reduction of Low-Density Lipoprotein Cholesterol by Monoclonal Antibody Inhibition of PCSK9

(2014) Evan A. Stein et al.   Annual Review of Medicine

B Cells and Humoral Immunity in Atherosclerosis

(2014) Dimitrios Tsiantoulas et al.   CIRCULATION RESEARCH

Anti-TNF therapy: past, present and future

(2014) C. Monaco et al.   INTERNATIONAL IMMUNOLOGY

Efficacy and safety of alirocumab, a monoclonal antibody to PCSK9, in statin-intolerant patients: Design and rationale of ODYSSEY ALTERNATIVE, a randomized phase 3 trial

(2014) Patrick M. Moriarty et al.   Journal of Clinical Lipidology

Anti-PCSK9 Antibody Effectively Lowers Cholesterol in Patients With Statin Intolerance

(2014) Erik Stroes et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Anti-PCSK9 Monotherapy for Hypercholesterolemia

(2014) Michael J. Koren et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

ICAM-1 signaling in endothelial cells

(2014) Charlotte Lawson et al.   Pharmacological Reports

Oxidation-specific epitopes and immunological responses: Translational biotheranostic implications for atherosclerosis

(2013) Gregor Leibundgut et al.   CURRENT OPINION IN PHARMACOLOGY

Effects of Interleukin-1β Inhibition With Canakinumab on Hemoglobin A1c, Lipids, C-Reactive Protein, Interleukin-6, and Fibrinogen

(2012) Paul M Ridker et al.   CIRCULATION

Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlled trial

(2012) Evan A Stein et al.   LANCET

Oxidized Low-Density Lipoprotein and Atherosclerosis Implications in Antioxidant Therapy

(2011) Sona Mitra et al.   AMERICAN JOURNAL OF THE MEDICAL SCIENCES